Payment overview · 2025
General Payments
$213.03
11 reported records · 7 companies
Healthcare provider profile · identity verified
Richard Gary Clark, MD
Allopathic & Osteopathic Physicians|Internal Medicine · JAMESTOWN, TN · NPI 1962406793
Verified facts
What the public records show
CMS Open Payments records show Richard Gary Clark, MD received $213.03 in general payments during 2025 across 11 reported records.
ABBVIE INC. accounted for 23.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Kerendia, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Ubrelvy by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Kerendia by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $50.16 | 23.6% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $37.67 | 17.7% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $36.37 | 17.1% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $33.14 | 15.6% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $23.46 | 11.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.62 | 8.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.61 | 6.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $213.03 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $50.16 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $37.67 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $36.37 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $33.14 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $23.46 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.62 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.62 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.61 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Kerendia kerendia |
2025 | Kerendia | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 35 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
35 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 1508 | 174 |
| Oxycodone Hcl | Oxycodone Hcl | 1326 | 147 |
| Gabapentin | Gabapentin | 1301 | 169 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 401 | 58 |
| Morphine Sulfate Er | Morphine Sulfate | 228 | 28 |
| Lisinopril | Lisinopril | 217 | 78 |
| Levothyroxine Sodium | Levothyroxine Sodium | 211 | 70 |
| Pregabalin | Pregabalin | 183 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 173 | 51 |
| Amlodipine Besylate | Amlodipine Besylate | 154 | 57 |
| Metoprolol Tartrate | Metoprolol Tartrate | 144 | 46 |
| Tizanidine Hcl | Tizanidine Hcl | 142 | 39 |
| Atorvastatin Calcium | Atorvastatin Calcium | 137 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 123 | 47 |
| Furosemide | Furosemide | 117 | 40 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 115 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 115 | 42 |
| Losartan Potassium | Losartan Potassium | 102 | 31 |
| Potassium Chloride | Potassium Chloride | 95 | 32 |
| Baclofen | Baclofen | 88 | 21 |
| Omeprazole | Omeprazole | 82 | 34 |
| Montelukast Sodium | Montelukast Sodium | 81 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 78 | 25 |
| Ondansetron Hcl | Ondansetron Hcl | 76 | 35 |
| Clonidine Hcl | Clonidine Hcl | 74 | 26 |
| Eliquis | Apixaban | 74 | 22 |
| Metformin Hcl | Metformin Hcl | 70 | 20 |
| Trazodone Hcl | Trazodone Hcl | 69 | 22 |
| Xtampza Er | Oxycodone Myristate | 69 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 62 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 62 | 25 |
| Jardiance | Empagliflozin | 61 | 11 |
| Meloxicam | Meloxicam | 59 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 58 | 24 |
| Kloxxado | Naloxone Hcl | 58 | 49 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 56 | 15 |
| Promethazine Hcl | Promethazine Hcl | 55 | 17 |
| Methocarbamol | Methocarbamol | 53 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 50 | 13 |
| Ibuprofen | Ibuprofen | 46 | 14 |
| Tamsulosin Hcl | Tamsulosin Hcl | 44 | 16 |
| Alprazolam | Alprazolam | 39 | 17 |
| Lorazepam | Lorazepam | 39 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | 12 |
| Fentanyl | Fentanyl | 37 | suppressed |
| Ozempic | Semaglutide | 35 | 16 |
| Simvastatin | Simvastatin | 35 | 16 |
| Buspirone Hcl | Buspirone Hcl | 34 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 34 | suppressed |
| Spironolactone | Spironolactone | 34 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 32 | 11 |
| Tramadol Hcl | Tramadol Hcl | 32 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Lamotrigine | Lamotrigine | 31 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 31 | 13 |
| Oxycontin | Oxycodone Hcl | 31 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 30 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 30 | 11 |
| Atenolol | Atenolol | 29 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 28 | suppressed |
| Oxymorphone Hcl Er | Oxymorphone Hcl | 27 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 27 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | suppressed |
| Mirtazapine | Mirtazapine | 26 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 26 | suppressed |
| Prednisone | Prednisone | 26 | 12 |
| Glimepiride | Glimepiride | 25 | suppressed |
| Clonazepam | Clonazepam | 23 | 11 |
| Farxiga | Dapagliflozin Propanediol | 23 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | 13 |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Lidocaine | Lidocaine | 21 | 11 |
| Celecoxib | Celecoxib | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Azithromycin | Azithromycin | 19 | 16 |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Rybelsus | Semaglutide | 19 | suppressed |
| Allopurinol | Allopurinol | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | 14 |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Ubrelvy | Ubrogepant | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | 12 |
| Kerendia | Finerenone | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | 11 |
| Nabumetone | Nabumetone | 11 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 11 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 11 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $213.03 · 11 records | ABBVIE INC. | BREZTRI, CAPLYTA, Cologuard Collection Kit, Kerendia, OTEZLA, Ozempic, REPATHA, Rybelsus, VRAYLAR | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Kerendia play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error